Overview

COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, initiative within the Mass General Brigham healthcare system testing two remote care strategies for optimizing the prescription of guideline-directed medical therapies in patients with heart failure, regardless of left ventricular ejection fraction (LVEF).
Phase:
Phase 4
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Boehringer Ingelheim
Treatments:
Adrenergic beta-Antagonists